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rep
Ed
MaOBJECTIVES The goal of this study was to evaluate the diagnostic performance of a comprehensive, multicompo-
nent cardiac magnetic resonance (CMR) study for assessment of left atrial (LA) and left atrial appendage (LAA)
thrombus.
BACKGROUND Pre-operative evaluation for pulmonary vein isolation (PVI) typically requires tomographic imaging to
deﬁne pulmonary venous anatomy and transesophageal echocardiogram (TEE) to assess for the presence of LA/LAA
thrombus. CMR is increasingly being used to deﬁne pulmonary venous anatomy before PVI. Limited data are available
on the utility of a multicomponent CMR protocol in assessing LA/LAA thrombus.
METHODS We studied patients who underwent multicomponent CMR for evaluation of pulmonary venous anatomy
before PVI and underwent TEE within 7 days. LA and LAA thrombi were evaluated by using CMR as follows: 1) cine-CMR;
2) contrast-enhanced magnetic resonance angiography; and 3) equilibrium phase delayed enhancement (DE) CMR with
a long inversion time (TI) of 600 ms (long TI DE-CMR). Components of the CMR study were evaluated for diagnostic
performance for detection of LA or LAA thrombus using TEE as the reference standard.
RESULTS During the study period, 261 patients were assessed. The median CHA2DS2VASc (congestive heart failure,
hypertension, age$75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex
category) score was 2, and 73.6% of patients were undergoing anticoagulation therapy. CMR and TEE were performed
within 1.3  2.3 days. LA/LAA thrombi were discovered in 9 patients (3.5%) by using TEE. Among the CMR techniques
performed, long TI DE-CMR had the highest diagnostic accuracy (99.2%), sensitivity (100%), and speciﬁcity (99.2%),
followed by contrast-enhanced magnetic resonance angiography (accuracy 94.3%; sensitivity 66.7%; and speciﬁcity
95.2%) and cine-CMR (accuracy 91.6%; sensitivity 66.7%; and speciﬁcity 92.5%).
CONCLUSIONS In patients referred for PVI, CMR could be a single complete diagnostic study for assessment of
pulmonary venous anatomy aswell as presence of LA/LAA thrombi, thus reducing the number of pre-operative tests before
PVI. Long TI DE-CMR has the best diagnostic performance and should be used for the detection of LA/LAA thrombi.
(J Am Coll Cardiol Img 2016;9:809–18) © 2016 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) is one of the mostcommonly encountered cardiac arrhythmiasin the United States as well as worldwide
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
CT = computed tomography
DE = delayed enhancement
LA = left atrial
LAA = left atrial appendage
MRA = magnetic resonance
angiography
PVI = pulmonary vein isolation
TEE = transesophageal
echocardiography
TI = inversion time
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810atrial contractile function are the major un-
derlying pathophysiology of thromboembo-
lism in patients with AF (3).
Pulmonary vein isolation (PVI) has evolved
as an effective therapeutic option for patients
with AF (1,4). As a part of the pre-operative
preparation, cardiac computed tomography
(CT) or cardiac magnetic resonance (CMR)
imaging is usually performed to provide a
precise map of the pulmonary venous anat-
omy (4). In addition, transesophageal echo-
cardiography (TEE) is frequently performed
before PVI to exclude the presence of left atrial
(LA) or LAA thrombus (4). TEE is currently
considered the gold standard for LA/LAA
thrombus detection given its favorable sensi-
tivity and speciﬁcity (1,4–6). With recentadvances, cardiac CT scanning is now becoming
another reliable diagnostic method for evaluation
of thrombus in the left atrium and LAA, particularly
when delayed imaging is performed (6). However, it
exposes patients to increased radiation doses and a
potential risk of contrast-induced nephropathy (6,7).SEE PAGE 819CMR is a useful imaging technique that can provide
valuable information in multiple clinical scenarios
such as assessment of myocardial viability, valvular
function, and evaluation of the vascular system (via
magnetic resonance angiography [MRA] or venog-
raphy) (8). Effectiveness of left ventricular thrombus
detection by CMR has been validated, and it is now
becoming a preferred imaging modality for evalua-
tion of left ventricular thrombus (8–10). To our
knowledge, there are few data regarding the utility of
CMR for detection of LA/LAA thrombus (11–13). The
goal of the present study was to systematically eval-
uate the diagnostic performance of a comprehensive
multicomponent CMR assessment for detection of
LA/LAA thrombus in patients referred for PVI.
METHODS
PATIENT SELECTION. From January 2009 to December
2014, all patients who were referred to the Houston
Methodist DeBakey Heart & Vascular Center CMR
Laboratory (Houston, Texas) for pulmonary venous
anatomy mapping by CMR with intravenous gado-
linium were enrolled into a registry. A comprehen-
sive medical history was obtained to calculate
CHA2DS2VASc (congestive heart failure, hyperten-
sion, $75 years of age, diabetes mellitus, stroke/
transient ischemic attack, vascular disease, 65 to
74 years of age, sex category) score. Only patientswho underwent TEE for assessment of LA/LAA
thrombus within 7 days of the CMR procedure were
included in this analysis. The study was approved
by the institutional review board of the Houston
Methodist Research Institute, and written informed
consent was obtained from all subjects.
CMR PROTOCOLS. CMR was performed with either
1.5- or 3-T whole-body clinical scanners (Siemens
Avanto and Siemens Verio; Siemens, Erlangen,
Germany) with phased-array coil systems. A multi-
component CMR that included evaluation of cardiac
function by cine-CMR, myocardial viability using
standard delayed enhancement (DE) CMR, and
contrast-enhanced MRA to evaluate pulmonary
venous anatomy were performed in all patients.
Evaluation for LA/LAA thrombus was conducted by
the following CMR components: 1) cine-CMR of the
left atrium and LAA in at least 2 orthogonal views
using a steady-state free-precession sequence with
typical repetition time of 3.0 to 3.5 ms, echo time
of 1.2 to 1.3 ms, in-plane spatial resolution of 2.0 
1.6 mm, slice thickness of 6 mm, and temporal reso-
lution of 35 to 40 ms; 2) nongated, contrast-enhanced
3-dimensional MRA during infusion of gadopente-
tate dimeglumine 0.15 mmol/kg, with image acquisi-
tion triggered when contrast was visualized in the
left atrium (arterial phase) using a gradient echo
sequence with ﬂip angle of 25 to 40, repetition time
of 2.4 to 2.9 ms, echo time of 0.8 to 1.1 ms, in-plane
spatial resolution of 1.5  1.3 mm, and slice thick-
ness of 1.5 mm (typical breath-holding time of 10 to
12 s); and 3) single-shot inversion recovery, steady-
state free-precession, multislice (covering entire left
atrium and LAA in 2 orthogonal planes), equilibrium
phase DE obtained approximately 10 min after intra-
venous gadolinium contrast administration using
long inversion time (TI) set at 600 ms (long TI
DE-CMR) to null avascular tissue with in-plane spatial
resolution of 2.1  1.6 mm, and slice thickness of
4 mm without gap. Breath-holding was not required
for the long TI DE-CMR sequence because each image
was acquired during mid-diastole within a single
heartbeat.
Brieﬂy, left and right ventricular volumes were
measured by planimetry of the endocardial borders
on a stack of short-axis images acquired from breath-
hold steady-state free-precession cines covering both
ventricles, from base to apex, 1 slice per breath-hold.
Papillary muscles and trabeculae were excluded from
the blood pool on the contours. Left and right ven-
tricular end-diastolic and end-systolic volumes were
calculated by summation of these images. Left and
right ventricular ejection fractions were determined
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811by subtracting the end-systolic volumes from the
end-diastolic volumes and dividing the result by the
end-diastolic volumes (14). The LA volume was
calculated according to the bi-plane method using
the LA area from 4- and 2-chamber long-axis images.
TEE PROTOCOL. TEE was performed with a 2- or
3-dimensional multiplane TEE probe by qualiﬁed
cardiologists who had COCATS level III training in
echocardiography. After the TEE probe was properly
positioned in the mid-esophagus, the examination of
the left atrium and LAA was performed according
to the TEE guidelines from the American Society of
Echocardiography (15). The left atrium and LAA were
thoroughly investigated for thrombi in multiplane
angles with particular attention to delineate the
pectinate muscles from thrombus. ProlongedFIGURE 1 Example of Thrombus in LAA
Thrombus in the left atrial appendage (LAA) (arrow) detected by (A) tran
enhanced magnetic resonance angiography (MRA), and (D) the equilibriu
Images refer to subject #4 in Table 2. LA ¼ left atrium; LV ¼ left ventrobservation in a single plane or using simultaneous
multiple-plane imaging was performed to differen-
tiate sludge or spontaneous echocardiographic
contrast from thrombus.
DEFINITION OF LA AND LAA THROMBUS. According to
TEE, thrombus was deﬁned as a well-circumscribed,
highly reﬂective mass of uniform consistency, with
texture different from the atrial wall and with a
border distinct from the surrounding structures
(15). Spontaneous echocardiographic contrast (“a
smoke-like’’ appearance, not well circumscribed,
and without a uniform consistency) was not consid-
ered as thrombus. Thrombus was classiﬁed as mural
thrombus if the borders were contiguous with adja-
cent LA or LAA contours. Thrombus size was
measured in its largest dimension.sesophageal echocardiography (TEE), (B) cine–cardiac magnetic resonance (CMR), (C) contrast-
m phase delayed enhancement CMR using a long inversion time of 600 ms (long TI DE-CMR).
icle.
TABLE 1 Baseline Characteristics and CMR Findings of Study Population
Total
(n ¼ 261)
Thrombus Present
(n ¼ 9)
Thrombus Absent
(n ¼ 252)
p
Value
Clinical parameters
Age, yrs 61.8  11.8 58.8  11.8 62.0  11.9 0.429
Male 181 (69.4) 4 (44.4) 177 (70.2) 0.138
Body surface area, kg/m2 2.1  0.3 2.1  0.4 2.1  0.3 0.99
Time between CMR and TEE, days 1.3  2.3 1.6  2.4 1.2  2.3 0.609
Heart failure 53 (20.3) 5 (55.6) 48 (19.0) 0.019
Hypertension 179 (68.6) 6 (66.7) 173 (68.7) 0.99
Diabetes 49 (18.8) 3 (33.3) 46 (18.3) 0.376
Coronary artery disease 51 (19.5) 4 (44.4) 47 (18.7) 0.076
History of stroke or TIA 24 (9.2) 0 (0.0) 24 (9.5)
Paroxysmal AF 150 (57.5) 3 (33.3) 147 (58.3) 0.176
AF during CMR procedure 109 (41.8) 5 (55.6) 104 (41.2) 0.497
CHA2DS2VASc score
<2 89 (34.1) 1 (11.1) 88 (34.9) 0.173
2–3 107 (41.0) 5 (55.6) 102 (40.5) 0.494
>3 65 (24.9) 3 (33.3) 62 (24.6) 0.695
Anticoagulation use 192 (73.6) 7 (77.8) 185 (73.4) 0.99
Antiplatelet use 80 (30.7) 3 (33.3) 77 (30.6) 0.99
CMR ﬁndings
LVEDV index, ml/m2 67.4  20.8 75.7  36.8 67.1  20.1 0.224
RVEDV index, ml/m2 69.3  22.5 62.2  26.6 69.6  22.4 0.334
Left atrial volume index, ml/m2 60.8  23.9 75.5  46.4 60.2  22.7 0.059
LV ejection fraction, % 59.0  13.6 49.4  22.6 59.4  13.1 0.030
RV ejection fraction, % 50.4  9.9 41.8  10.6 50.7  9.8 0.008
LV mass index, g/m2 68.1  20.8 72.3  20.9 68.0  20.8 0.543
Values are mean  SD or n (%). Values of p < 0.05 indicate statistical signiﬁcance. Normal values for variables as
follows: LVEDV index ¼ 57 to 105 ml/m2 for men and 56 to 96 ml/m2 for women; RVEDV index ¼ 61 to 121 ml/m2
for men and 48 to 112 ml/m2 for women; LA volume index ¼ 26 to 52 ml/m2 for men and 27 to 53 ml/m2 for
women; LV ejection fraction ¼ 57% to 77%; RV ejection fraction ¼ 52% to 72%; LV mass index ¼ 49 to 85 g/m2
for men and 41 to 81 g/m2 for women (18).
AF ¼ atrial ﬁbrillation; CHA2DS2VASc ¼ congestive heart failure, hypertension, $75 years of age, diabetes
mellitus, stroke/transient ischemic attack, vascular disease, 65 to 74 years of age, sex category; CMR ¼ cardiac
magnetic resonance; LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic volume; RV ¼ right ventricular;
RVEDV ¼ right ventricular end-diastolic volume; TEE ¼ transesophageal echocardiography; TIA ¼ transient
ischemic attack.
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812For cine-CMR, thrombus was deﬁned as a mass
within the LA or LAA cavity that had margins distinct
from the LA or LAA wall and distinguishable from
pectinate muscles or technical artifact (9). Using
contrast-enhanced MRA, a low signal intensity ﬁlling
defect in the left atrium or LAA that had borders
discrete from surrounding structures or blood pool
was interpreted as thrombus (13). Thrombus was
diagnosed on long TI DE-CMR as a mass with post-
contrast characteristics consistent with avascular
tissue (9). Typically, thrombus appeared as homoge-
neously black on long TI DE-CMR surrounded by
high signal intensity structures of blood pool cavity.
All TEE and CMR studies were interpreted by 2
readers who have COCAT level III training in TEE
and CMR. All readers were blinded to clinical history
and results of other imaging studies. Individual
CMR components were evaluated separately and in
random order. Using consensus of the 2 readers, CMRand TEE were classiﬁed to “thrombus” or “no
thrombus” in the left atrium and LAA. The CMR study
was identiﬁed as “possible thrombus” when LA or
LAA thrombus could not be excluded. Speciﬁcally, for
contrast-enhanced MRA, the study would not be
interpreted as abnormal when thrombus could be
excluded due to incomplete contrast opaciﬁcation of
the left atrium or LAA; rather, it would be classiﬁed
as “possible thrombus.” Figure 1 displays an example
of an LAA thrombus detected by using TEE and
multicomponent CMR in the same patient.
STATISTICAL ANALYSIS. All data are presented as
mean  SD for continuous variables and frequency
or median with interquartile ranges for categorical
variables. Patients with and without thrombus were
compared using an unpaired Student t test for
continuous variables and the Fisher exact test for
categorical variables. Diagnostic performance of each
CMR component (including sensitivity, speciﬁcity,
positive predictive value, negative predictive value,
and diagnostic accuracy with 95% conﬁdence in-
tervals [CIs]) were calculated in a standard manner.
To determine the diagnostic performance of each
CMR component, using rational intention to exclude
thrombus, the studies categorized as possible
thrombus were included in the thrombus group
for further analysis. Interobserver agreement for
thrombus identiﬁcation was calculated using the
kappa coefﬁcient. Values of p < 0.05 were considered
statistically signiﬁcant.
RESULTS
During the study period, 261 multicomponent CMR
studies met the inclusion criteria and were included
for further analysis. The patient baseline character-
istics are summarized in Table 1. The majority of the
patients in the study cohort were male (69.4%), with
a mean age of 61.8  11.8 years. Hypertension was the
most common comorbidity (68.6%), and 24 patients
(9.2%) had a history of stroke or transient ischemic
attack. AF was recorded as the cardiac rhythm during
the CMR procedure in 109 patients (41.8%). The car-
diac rhythm at the time of CMR and TEE were
different in 7 patients: 3 patients were in AF during
the time of CMR but in sinus rhythm at the time of
TEE, and 4 patients were in sinus rhythm at the time
of CMR but in AF during the TEE procedure. Of note,
thrombus was not detected by CMR or TEE in any
of these patients. The median CHA2DS2VASc score
was 2 (interquartile range: 1 to 3). Anticoagulation use
was reported in 192 patients (73.6%) during the time
of CMR examination. In our institution, a patient
who is undergoing anticoagulation therapy will be
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813continued on therapeutic anticoagulation throughout
the pre-procedural period until the day of the PVI
procedure.
CMR ﬁndings are shown in Table 1. Left and right
ventricular size and systolic function were noted
to be within normal range. However, the mean LA
volume index (60.8  23.9 ml/m2) was increased
in the study cohort. The patients with presence of
LA/LAA thrombus had higher prevalence of heart
failure and lower left and right ventricular ejection
fraction compared with those without. In patients
with LA/LAA thrombus, the median CHA2DS2VASc
score was 3.
There were no complications from TEE or CMR
noted for the study patients. According to TEE, LA
and LAA thrombi were detected in 9 studies (3.5%)
as shown in Table 2. Thrombi were found in the
LAA in 7 studies (2.7%) and in the left atrium in 2
studies (0.8%). Long TI DE-CMR was able to identify
all cases of thrombi detected by using TEE. Cine-CMR
could not identify thrombi in 3 studies in which all
LAA thrombus size was found to be #0.9 cm accord-
ing to TEE. Contrast-enhanced MRA was not able to
detect thrombus in 3 studies (2 laminated mural
LA thrombi and 1 LAA thrombus). Figures 2 and 3
illustrate example cases that long TI DE-CMR could
correctly identify thrombus in the left atrium or
LAA, whereas the other investigated CMR compo-
nents could not. Of 9 patients initially found to have
thrombus according to TEE, 5 underwent PVI after
anticoagulation therapy; repeated imaging (3 had
repeat CMR) demonstrated no evidence of thrombus
in the left atrium or LAA. Among the 249 patients
(95.4%) who subsequently underwent PVI (including
5 patients previously identiﬁed with thrombus), no
stroke or transient ischemic attack was reported
post-procedure.
The interobserver agreement was highest in long
TI DE-CMR (kappa ¼ 0.91; 95% CI: 0.78 to 1.0) fol-
lowed by cine-CMR (kappa ¼ 0.85; 95% CI: 0.74 to
0.97) and contrast-enhanced MRA (kappa ¼ 0.83; 95%
CI: 0.69 to 0.98). Diagnostic performance of LA/LAA
thrombus detection by each CMR component is
demonstrated in Figure 4. Among CMR sequences
investigated in the study, long TI DE-CMR had the
best diagnostic accuracy (99.2%; 95% CI: 97.2% to
99.9%), sensitivity (100%; 95% CI: 66.4% to 100%),
speciﬁcity (99.2%; 95% CI: 97.2% to 99.9%), positive
predictive value (81.8%; 95% CI: 48.2% to 97.7%), and
negative predictive value (100%; 95% CI: 98.5% to
100%). In contrast, cine-CMR had the lowest diag-
nostic accuracy of 91.6% (95% CI: 87.5% to 94.6%),
sensitivity of 66.7% (95% CI: 29.9% to 2.5%), speci-
ﬁcity of 92.5% (95% CI: 88.5% to 95.4%), and a
FIGURE 2 Example of Mural Thrombus in the Posterior LA Wall
Laminated mural thrombus in the posterior left atrial (LA) wall (arrow) detected by (A) TEE, (B) cine-CMR, and (D) long TI DE-CMR. (C)
Contrast-enhanced MRA was not able to identify this mural thrombus. Images refer to subject #2 in Table 2. Abbreviations as in Figure 1.
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814positive predictive value of 24% (95% CI: 9.4% to
45.1%). All of the CMR sequences had a high negative
predictive value, ranging from 98.7% by cine-CMR to
100% by long TI DE-CMR. Cine-CMR and contrast-
enhanced MRA were not able to exclude LA/LAA
thrombus, resulting in a possible thrombus interpre-
tation in 18 studies (6.9%) and 12 studies (4.6%),
respectively, whereas 2 studies (0.8%) were inter-
preted as possible thrombus according to long TI
DE-CMR.
In our investigation, 143 studies (54.8%) were
performed on a 3-T scanner, and 118 studies (45.2%)
were performed on a 1.5-T scanner. The diagnostic
accuracy of the investigated CMR components per-
formed by using the 3- or 1.5-T scanners was not
signiﬁcantly different, and long TI DE-CMR remains
the CMR component that has the highest diagnostic
accuracy on both scanners (99.3% [3-T] vs. 99.1%
[1.5-T]; p ¼ 0.99) followed by contrast-enhanced
MRA (95.8% [3-T] vs. 92.4% [1.5-T]; p ¼ 0.289)
and cine-CMR (93.0% [3-T] vs. 89.8% [1.5-T]; p ¼
0.379). Although the diagnostic accuracy of long TI
DE-CMR (98.2% [AF] vs. 100% [no AF]; p ¼ 0.174),contrast-enhanced MRA (93.6% [AF] vs. 94.7% [no
AF]; p ¼ 0.789), and cine-CMR (88.1% [AF] vs. 94.1%
[no AF]; p ¼ 0.113) in patients with AF during the time
of the CMR procedure was less than in those without
AF, the ﬁndings were not statistically signiﬁcant.
DISCUSSION
Our study is the largest investigation to date to
evaluate the utility of CMR in assessment of LA/LAA
thrombus in patients referred for PVI. The result
of our study showed that multicomponent CMR is
a feasible diagnostic modality for assessment of
LA/LAA thrombus. For patients referred for PVI,
multicomponent CMR can be a single comprehensive
study that provides pulmonary venous anatomy
mapping and simultaneously evaluates the presence
of thrombus in the left atrium or LAA. This ﬁnding
could potentially reduce the amount of pre-operative
testing and overall procedure cost for patients
referred for PVI.
Despite the high negative predictive value for
LA/LAA thrombus detection found in all investigated
FIGURE 3 Example of Small LAA Thrombus
Example of small LAA thrombus (arrow) detected by (A) TEE and (D) long TI-DE-CMR. LAA thrombus could not be excluded by (B) cine-CMR,
whereas (C) contrast-enhanced MRA failed to identify LAA thrombus. Images refer to subject #9 in Table 2. Abbreviations as in Figure 1.
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815CMR components, the diagnostic performance of long
TI DE-CMR was superior to other CMR components
and was not affected by the use of a 1.5- or 3-T scanner
or the presence of AF at the time of the CMR proce-
dure. For assessment of thrombus, long TI DE-CMR
can provide additional advantages over standard
DE-CMR as shown in a previous study (9). Weinsaft
et al. (9) validated the ability of long TI DE-CMR for
detection of left ventricular thrombus and also
showed the superiority of this technique over cine-
CMR. Similar to this study in which cine-CMR gener-
ally missed small left ventricular thrombus, cine-CMR
in our study was not able to identify the presence of
thrombus in studies with small LAA thrombi.
CMR protocols used for the evaluation of
LA/LAA thrombus in previous studies carried certain
limitations. Double and triple inversion recovery se-
quences are susceptible to ﬂow-related enhancementartifacts that can interfere with LA and LAA thrombus
evaluation (12). The 2-dimensional CMR perfusion is
limited by spatial resolution and imaging plane dur-
ing perfusion (13). Spatial resolution and image
contrast between background and LA/LAA wall, as
well as slow ﬂow in the left atrium and LAA,
can affect evaluation of thrombus by 3-dimensional
contrast-enhanced CMR (11,13). Imaging artifacts
are also commonly encountered in cine-CMR; these
include breathing motion, ﬂow-related, and inhomo-
geneity artifacts (16). Accordingly, in our study,
thrombus could not be excluded by using cine-
CMR and contrast-enhanced MRA in a number of
patients. These were caused by ﬂow-related and
inhomogeneity artifacts in the majority of cine-
CMR studies, whereas underﬁlled LAA due to slug-
gish ﬂow in LA and LAA were typically seen in
contrast-enhanced MRA. Long TI DE-CMR provided
FIGURE 4 Diagnostic Performance of Each CMR Component
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Long TI DE-CMR was able to identify all thrombus detected by TEE. Despite a high negative predictive value, cine-CMR and contrast-enhanced
MRA could not exclude thrombus in 6.9% and 4.6%, respectively, resulting in a low positive predictive value. Long TI DE-CMR had the highest
diagnostic performance for detection of LA/LAA thrombus in all categories compared with other CMR components. Abbreviations as in Figure 1.
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816advantages over other CMR components in multiple
ways. Figure 5 illustrates a case with no LA/LAA
thrombus documented by TEE, but only long DE-CMR
could exclude the presence of thrombus while other
investigated CMR components could not. Multislice,
long TI DE-CMR provided adequate coverage of the
entire left atrium and LAA, but it is less susceptible to
artifact and could prevent the situation of underﬁlled
LAA because it was performed with a single-shot
technique in the equilibrium phase, 10 min after
contrast administration. In addition, due to the rapid
acquisition time of this technique, breath-holding
was not required; it could also be performed in the
setting of irregular cardiac rhythm, which might
be encountered in patients with AF before PVI. As
shown in our analysis, long TI DE-CMR had only
a few studies in which LA/LAA thrombus could not be
excluded, resulting in a better positive predictive
value and diagnostic performance than the other CMR
components. In fact, in our study, ﬁndings from cine-
CMR and contrast-enhanced MRA provided no further
information regarding LA/LAA thrombus assessment
in addition to what long TI DE-CMR had already
provided. With these available data, long TI DE-CMR
is the preferable CMR sequence and should be used
for LA/LAA thrombus detection.To our knowledge, there is no previous study
directly comparing cardiac CT and CMR scans for
LA/LAA thrombus detection in this clinical setting.
The longer time required for CMR examination has
been commonly criticized as a disadvantage of CMR.
In fairness, if the CMR protocols were tailored to
evaluate pulmonary venous anatomy and identify
LA/LAA thrombus, the image acquisition time could
be signiﬁcantly reduced, although not as short as in
cardiac CT scans. In contrast to cardiac CT scanning,
CMR could provide valuable data for PVI procedures
without exposure to radiation. This scenario might
be even more important in certain patients who are
expected to have a long PVI procedure time or a
repeat procedure in the future. The criteria in cardiac
CT scanning that are used to determine the presence
of thrombus rely on detection of low attenuation
regions, which can occasionally can be difﬁcult to
differentiate from sluggish blood ﬂow in the left
atrium/LAA that may be seen in patients with AF
(6). Tissue characterization is a unique advantage of
CMR that provides further information in thrombus
assessment and would not be affected by slow ﬂow
in the left atrium or LAA. In addition, the extent of
LA ﬁbrosis or scarring can be assessed by DE-CMR
and may be of value in selected patients (4).
FIGURE 5 Example of Normal Study Without Thrombus Detected by TEE
In this example, no thrombus was identiﬁed by TEE. LAA thrombus could not be excluded by (A) cine-CMR due to ﬂow-related artifact in the LAA (arrow) and by (B)
contrast-enhanced MRA due to underﬁlled LAA (thin arrow); however, with (C) long TI DE-CMR, LAA (arrowhead) can be clearly visualized and without the presence of
thrombus. Abbreviations as in Figure 1.
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817STUDY LIMITATIONS. Similar to cardiac CT scanning,
the diagnostic performance of contrast-enhanced
MRA was affected by underﬁlled LAA, which com-
plicated differentiation between thrombus and slug-
gish blood ﬂow (6). Cardiac CT scans with delayed
images (typically 30 to 180 s after contrast injection)
has been shown to improve the diagnostic accuracy
of LA/LAA thrombus detection from 90% to 99%.
Likewise, using delayed contrast-enhanced MRA
images may help improve diagnostic accuracy for
LA/LAA thrombus detection with this technique. The
utility of phase sensitive inversion recovery DE-CMR
was not evaluated in our study. It should be noted
that with a routine DE-CMR utilizing a TI set to null
myocardium, thrombus may appear grey with a black
rim on magnitude images; however, with phase-
sensitive inversion recovery DE-CMR that recon-
structed and discriminated positive and negative
signal amplitude, thrombus appear black and is easy
to identify. The phase-sensitive inversion recovery
sequence could potentially be another method of
thrombus imaging that does not require additional
TI adjustment. Unlike TEE that could provide both
anatomical and physiological data such as LAA
emptying velocity, the CMR components evaluated inour study could only provide anatomical data (17).
It is known that prevalence can affect diagnostic
performance of a test and therefore the performance
characteristics of the CMR components in our study
needs to be interpreted with this fact in mind.
However, multiple studies using cardiac CT scanning
to evaluate LA/LAA thrombus with TEE as the refer-
ence standard in the setting of PVI demonstrated an
incidence/prevalence of LA/LAA thrombus of 2% to
19% (6), which appears in line with our data, thus
supporting the generalizability of our ﬁndings.
Despite being the largest study to evaluate the diag-
nostic performance of CMR in assessing LA/LAA
thrombus, the results of our study reﬂect the expe-
rience from a single center. Further multicenter
studies with larger sample sizes are necessary to
conﬁrm our ﬁndings.
CONCLUSIONS
In patients referred for PVI, CMR is a noninvasive test
that has a favorable diagnostic performance and
could be an alternative imaging modality to TEE for
assessment of LA/LAA thrombus. In our study, long
TI DE-CMR was shown to be the most reliable CMR
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
CMR may be a comprehensive test for evaluation of
pulmonary venous anatomy and LA/LAA thrombus in
patients referred for PVI.
TRANSLATIONAL OUTLOOK: Future multicenter
studies are needed to conﬁrm the utility of CMR as
a comprehensive test before the PVI procedure.
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818sequence and should be used for LA/LAA thrombus
detection. CMR may be a single comprehensive diag-
nostic study to assess pulmonary venous anatomy
as well as the presence of LA/LAA thrombus, thus
potentially reducing the number of pre-operative tests
before PVI.
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